Emerging chemical strategies for CD38 inhibition: restoring NAD

Zeyu Zhang, Arshad J Ansari, Ethan R Fayne, Yong Zhang

Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States. · pubmed

Paper

Abstract

Cluster of differentiation 38 (CD38) is a multifunctional ectoenzyme regulating immune functions, calcium signaling, and nicotinamide adenine dinucleotide (NAD

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

This paper reviews chemical strategies for inhibiting CD38 to restore NAD+ levels, a mechanism linked to mitigating age-related metabolic decline and stem cell exhaustion. The relevance stems from targeting a fundamental driver of aging (NAD+ depletion) rather than treating specific age-related symptoms, although the impact is limited as it is a review of existing strategies rather than a novel breakthrough.

Author of this paper? Send a correction.